## **Core Concept**
Axicabtagene ciloleucel is a type of **CAR-T cell therapy**, which involves genetically modifying a patient's T cells to express a chimeric antigen receptor (CAR) that targets a specific antigen on cancer cells. This therapy is used in the treatment of certain types of blood cancers.

## **Why the Correct Answer is Right**
Axicabtagene ciloleucel is specifically approved for the treatment of **relapsed or refractory large B-cell lymphoma (LBCL)**, including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and transformed follicular lymphoma (TFL). The CAR-T cells in axicabtagene ciloleucel are engineered to target the **CD19 antigen**, which is expressed on the surface of B cells, including malignant B cells in LBCL.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because axicabtagene ciloleucel is not primarily used for the treatment of solid tumors.
- **Option B:** This option is incorrect as there is no widely recognized indication of axicabtagene ciloleucel in the treatment of multiple myeloma; other CAR-T cell therapies like tisagenlecleucel and daratumumab are being explored for multiple myeloma.
- **Option C:** This option is incorrect because while CAR-T cell therapies are being explored for various hematological malignancies, axicabtagene ciloleucel's primary indication is not for acute myeloid leukemia (AML).

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **CAR-T cell therapies like axicabtagene ciloleucel can cause significant side effects**, including cytokine release syndrome (CRS), which can be life-threatening. Monitoring and management of these side effects are critical for the safe administration of these therapies.

## **Correct Answer:** D. Relapsed or refractory large B-cell lymphoma.